

1 **Title: Head-to-head comparison of diagnostic accuracy of TB screening tests: Chest-X-**  
2 **ray, Xpert TB host response, and C-reactive protein**

3  
4 **Authors:** Rebecca Crowder<sup>1</sup>, Balamugesh Thangakunam<sup>2</sup>, Alfred Andama<sup>3</sup>, Devasahayam J  
5 Christopher<sup>2</sup>, Victoria Dalay<sup>4</sup>, Welile Dube-Nwamba<sup>5</sup>, Sandra V. Kik<sup>6</sup>, Dong Van Nguyen<sup>7</sup>,  
6 Nguyen Viet Nhung<sup>8</sup>, Patrick PJ Phillips<sup>1</sup>, Morten Ruhwald<sup>6</sup>, Grant Theron<sup>5</sup>, William  
7 Worodria<sup>3</sup>, Charles Yu<sup>4</sup>, Payam Nahid<sup>1</sup>, Adithya Cattamanchi<sup>9</sup>, Ankur Gupta-Wright<sup>10-11</sup>,  
8 Claudia M. Denkinger<sup>10,12</sup> for the R2D2 TB Network

- 9  
10 1. Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, University  
11 of California San Francisco, San Francisco, USA.  
12 2. Christian Medical College, Vellore, India.  
13 3. Makerere University, Kampala, Uganda.  
14 4. De la Salle Medical and Health Sciences Institute, Dasmariñas, Philippines.  
15 5. Stellenbosch University, Cape Town, South Africa.  
16 6. FIND, Geneva, Switzerland.  
17 7. Hanoi Lung Hospital, Hanoi, Vietnam.  
18 8. Vietnam National Lung Hospital, NTP, HMU, Hanoi, Vietnam.  
19 9. Division of Pulmonary Diseases and Critical Care Medicine, University of California  
20 Irvine, Irvine, CA.  
21 10. Division of Infectious Disease and Tropical Medicine, University Hospital of Heidelberg,  
22 Heidelberg, Germany.  
23 11. Department of Infectious Diseases, Imperial College London, UK.  
24 12. German Center of Infection Research, partner site Heidelberg, Germany.

25  
26 **Corresponding author:**  
27 Claudia Denkinger  
28 [Claudia.Denkinger@uni-heidelberg.de](mailto:Claudia.Denkinger@uni-heidelberg.de)

29  
30 Abstract: 321  
31 Word count: 3,092  
32 Tables and figures: 5

33

1 **ABSTRACT**

2

3 **Background:** Accessible, accurate screening tests are necessary to advance tuberculosis (TB)  
4 case finding and early detection in high-burden countries. We compared the diagnostic  
5 accuracy of available TB triage tests.

6

7 **Methods:** We prospectively screened consecutive adults with  $\geq 2$  weeks of cough presenting  
8 to primary health centers in the Philippines, Vietnam, South Africa, Uganda, and India. All  
9 participants received the index tests: chest-X-ray (CXR), venous or capillary Cepheid Xpert  
10 TB Host Response (HR) testing, and point-of-care C-reactive protein (CRP) testing (Boditech  
11 iChroma II). CXR images were processed using computer-aided detection (CAD) algorithms.  
12 We assessed diagnostic accuracy against a microbiologic reference standard (sputum Xpert  
13 Ultra, culture). Optimal cut-points were chosen to achieve sensitivity  $\geq 90\%$  and maximize  
14 specificity. Two-test screening algorithms were considered, using two approaches: 1)  
15 sequential negative serial screening in which the second screening test is conducted only if the  
16 first is negative and positive is defined as positive on either test and 2) sequential positive serial  
17 screening, in which the second screening test is conducted only if the first is positive and  
18 positive is defined as positive on both tests.

19

20 **Results:** Between July 2021 and August 2022, 1,392 participants with presumptive TB had  
21 valid results on index tests and the reference standard, and 303 (22%) had confirmed TB. In  
22 head-to-head comparisons, CAD4TB v7 showed the highest specificity when using a cut-point  
23 that achieves 90% sensitivity (70.3% vs. 65.1% for Xpert HR, difference 95% CI 1.6 to 8.9;  
24 49.7% for CRP, difference 95% CI 17.0 to 24.3). Among the possible two-test screening  
25 algorithms, three met WHO target product profile (TPP) minimum accuracy thresholds and  
26 had higher accuracy than any test alone. At 90% sensitivity, the specificity was 79.6% for Xpert  
27 HR-CAD4TB [sequential negative], 75.9% for CRP-CAD4TB [sequential negative], and  
28 73.7% for Xpert HR-CAD4TB [sequential positive].

29

30 **Conclusions:** CAD4TB achieves TPP targets and outperforms Xpert HR and CRP. Combining  
31 screening tests further increased accuracy. Cost and feasibility of two-test screening algorithms  
32 should be explored.

33

34 **Registration:** NCT04923958

## 1 INTRODUCTION

2 Approximately 7.5 million people were diagnosed with Tuberculosis (TB) in 2022 and 1.3  
3 million people died from the disease [1]. Globally, 3.1 million TB cases were undiagnosed or  
4 unreported in 2022 [1]. This demonstrates that access to high-quality and affordable TB testing  
5 remains limited, making TB diagnosis the weakest link in the TB cascade of care. World Health  
6 Organization (WHO) target product profiles (TPPs) for TB diagnostics prioritize a simple, low-  
7 cost, non-sputum-based point-of-care (POC) triage or screening test to rule-out TB and guide  
8 confirmatory testing [2].

9  
10 Promising TB triage tests include improvements on established technologies, such as chest X-  
11 ray (CXR); new application of existing tests, such as C-reactive protein (CRP); and novel  
12 assays, including the Xpert TB Host Response (Xpert HR) cartridge (Cepheid, Sunnyvale,  
13 USA). CXR implementation for TB screening has been limited in resource-constrained settings  
14 due to centralized CXR infrastructure [3] and scarcity of skilled personnel for interpretation  
15 [4]. The advent of digital CXR with computer-aided detection (CAD) analysis may reduce  
16 barriers to CXR screening by quickly enabling screening without the need for a skilled reader  
17 [5, 6]. However, performance varies by population screened, and limited data are available for  
18 children [7-10]. CRP is a non-specific marker for inflammation that has shown better accuracy  
19 than symptom screening for TB among people living with HIV (PLHIV) [11]. High CRP levels  
20 correlate with mycobacterial load and are associated with poor prognostic clinical features and  
21 a higher risk of death [12, 13]; however, CRP alone has not been shown to meet TPP specificity  
22 targets [11, 12, 14]. The recently developed Xpert HR assay detects expression levels of three  
23 host genes in whole blood. Results from early studies found that this assay approaches WHO  
24 minimum accuracy targets for a non-sputum-based triage test [15, 16].

25  
26 Direct comparison of diagnostic accuracy, alongside comparisons of cost and operational  
27 characteristics, are needed to guide policy decisions around the implementation of novel TB  
28 screening tests and assess consistency with TPP targets. Testing algorithms that combine  
29 available tests may be needed to meet desired characteristics. CXR combined with CAD as a  
30 second screening test is considered a possible option by WHO. We aimed to conduct a head-  
31 to-head comparison of the diagnostic accuracy of three potential TB screening tests, including  
32 CAD, CRP, and Xpert HR in a large multi-country cohort of people with presumptive TB.

## 33 METHODS

34  
35  
36 **Study design, population, and procedures.** In this prospective study, we screened adults ( $\geq 18$   
37 years) presenting to primary health centers with presumed TB between July 2021 and August  
38 2022 in the Philippines, Vietnam, Uganda, South Africa, and India. Specific enrollment  
39 locations have been reported previously [16] and are listed in the Appendix (**Appendix Table**  
40 **S1**). We enrolled consecutive outpatients if they had  $\geq 2$  weeks of new or worsening cough. We  
41 excluded people who had completed treatment for TB infection or disease within the past 12  
42 months, had taken antibiotics with anti-mycobacterial activity within 2 weeks of study entry,  
43 or were unable or unwilling to return for follow-up or provide informed consent. All  
44 participants had HIV and diabetes screening (using HbA1c), and 2-3 spot sputum samples were  
45 collected for reference standard testing (sputum was induced if unable to expectorate  
46 spontaneously). Study participants received CXR, provided venous or capillary blood for Xpert  
47 HR testing, and provided capillary blood for CRP testing.

48  
49 **Index testing.** All participants underwent antero-posterior or postero-anterior CXR at baseline.  
50 If digital CXR was not available, analog CXR images were scanned to create jpeg images which

1 were then converted into DICOM format using the img2dcm tool from the dcmtoolkit  
2 (v3.6.6). Images that did not fulfill the DICOM features that were required for successful CAD  
3 software processing were subsequently modified using the dcmmodify tool (v3.6.6) from the  
4 dcmtoolkit before they were processed with the CAD software. Images were processed using  
5 five different CAD algorithms, but based on previous analysis [17], we chose the best  
6 performing CAD algorithm, CAD4TB v7, (CAD4TB), to be evaluated for comparisons in this  
7 analysis. CAD analysis was conducted by FIND, according to the developers' instructions.  
8 CAD4TB produces a TB score, ranging from 0 to 100.

9  
10 The Xpert® MTB-HR Research-Use-Only (RUO) prototype cartridge evaluates mRNA levels  
11 of four differentially expressed genes (GBP5, DUSP3, KLF2 and TBP). Testing involved  
12 inoculating the cartridge by transferring 100 µL of freshly collected whole or capillary blood  
13 in an EDTA tube into the cartridge chamber and analyzing using the GeneXpert instrument as  
14 per manufacturer instructions. We calculated the 'TB score' using the formula  $(Ct\ GBP5 + Ct$   
15  $DUSP3)/2 - Ct\ TBP$  as previously described [16].

16  
17 CRP concentrations were measured at baseline from capillary blood using a United States Food  
18 and Drug Administration-approved standard sensitivity POC assay, measured using ichroma II  
19 (Boditech Med Inc., Chuncheon-si, South Korea) that provides quantitative results in three  
20 minutes (range: 2.5-300 mg/L). A fixed-volume micropipette (50 µL) was used to obtain and  
21 transfer capillary blood to a reagent tube, mixed, and two drops were applied on the lateral-  
22 flow device for testing.

23  
24 No pre-specified cut-point was provided for any index test. All operators performing the index  
25 and reference tests were blinded to clinical details and other TB testing results.

26  
27 **Reference standard testing.** Each participant provided 2-3 sputum samples, and the  
28 microbiologic reference standard (MRS) was determined by results from sputum Xpert Ultra  
29 MTB/RIF (Cepheid, Sunnyvale, USA) and mycobacterial culture (MGIT, Becton Dickinson,  
30 USA; solid culture in 7h10 media was used when MGIT supplies were not available). A  
31 positive reference standard was defined as a positive sputum Xpert Ultra result (grade 'very  
32 low' or higher, or two 'trace' results) or a positive culture. Participants with a positive Xpert  
33 Ultra result did not undergo confirmatory culture. A negative reference standard was defined  
34 as no positive results on Xpert Ultra or culture and two negative cultures. Those not meeting  
35 the criteria for positive or negative were defined as indeterminate and excluded from the  
36 analysis.

37  
38 In addition, we used a secondary, simplified sputum Xpert Ultra reference standard given that  
39 a molecular test is typically the only confirmatory TB test available in programmatic settings.

40  
41 **Statistical Analysis.** For each index test, we conducted receiver operating characteristic (ROC)  
42 analysis to compute the area under the curve (AUC) with 95% confidence interval (CI).  
43 Participants with indeterminate index test results were excluded from the analysis. For the  
44 primary analysis, optimal cut-points were chosen for each test that would achieve the TPP  
45 target sensitivity  $\geq 90\%$  and maximize specificity in the overall population. Two-test screening  
46 algorithms were also considered. We considered 1) a sequential negative serial screening  
47 approach [18], in which the second screening test is conducted only if the first is negative and  
48 a positive screen is defined as positive on either test and 2) a sequential positive serial screening  
49 approach [18], in which the second screening test is conducted only if the first is positive and  
50 a positive screen is defined as positive on both tests (**Appendix Figure S1**). We considered

1 CRP and Xpert HR the more likely initial test, followed by the CAD, given the infrastructure  
2 requirements necessary for CXR and CAD. For each potential combination, we considered  
3 1,000 possible combinations of cut-points (100 possible cut-points for the first test and 100  
4 possible cut-points for the second test). We then identified all pairs of cut-points that would  
5 achieve sensitivity  $\geq 90\%$  and specificity  $\geq 70\%$ , then likewise selected the pair that achieved  
6 the highest possible specificity within these constraints. With all binary tests set to have a  
7 sensitivity of 90%, our primary analysis compared the specificity of each index alone and the  
8 possible combined two-test screening algorithms among the entire study population. The  
9 absolute difference in specificity for each pairwise comparison was calculated using  
10 McNemar's test for paired proportions. Results are reported following STARD guidance [19].  
11 Secondary analyses compared the sensitivity and specificity of the index tests alone and in  
12 combination among subgroups of interest (by country, HIV status, diabetes status). A sample  
13 size of 1,500 (300 per country) was pre-specified to achieve reasonable confidence interval  
14 widths between 5.2-9.4% depending on observed test sensitivity (80-95%) and 4.6%-5.6%  
15 depending on observed test specificity (60-80%) when assuming a TB prevalence of 20%. Stata  
16 version 18 was used for all analyses.

17  
18 **Ethics.** This study was registered with ClinicalTrials.gov (NCT04923958). Study procedures  
19 were approved by the institutional review board (IRB) of the University of California San  
20 Francisco, the University of Heidelberg, and by local IRBs at each enrollment site (**Appendix**  
21 **Table S1**).

22  
23 **Funding.** This work was supported by the United States National Institute of Allergy and  
24 Infectious Diseases [U01AI152087]. POC CRP test kits and ichroma II machines were donated  
25 by Boditech Med Inc, and Xpert HR test kits were donated by Cepheid. CAD was performed  
26 by FIND at no cost to the study. The installation and use of the CAD4TB software evaluated  
27 in this manuscript was provided free of charge by Delft Imaging to FIND. Study funders and  
28 product developers had no role in study design, data collection, data analysis, data  
29 interpretation, or writing.

## 30 31 **RESULTS**

32  
33 **Participants.** Between July 2021 and August 2022, 2,046 adults were screened across clinical  
34 sites in five countries (the Philippines, Vietnam, Uganda, South Africa, and India). 1,666 (81%)  
35 met the criteria for inclusion in the study, of which 1,561 (94%) received all three tests. 31  
36 (2%) CAD4TB readings, 27 (2%) Xpert HR results, and no CRP results were indeterminate or  
37 invalid. 1,392 (89%) participants had all three index tests and the microbiologic reference  
38 standard performed with valid results (**Figure 1**). Of the 1,392 assessable participants, 46%  
39 were female, the median age was 43, 14% were living with HIV (median CD4 count 378), and  
40 14% were living with diabetes (median HbA1c 7.0) (**Table 1**). In total, 303 (22%) had  
41 microbiologically confirmed TB. However, characteristics varied by country (**Table 1**), with  
42 TB prevalence ranging from 9% in India and the Philippines to 38% in Vietnam.

43  
44 Xpert HR was conducted using venous (82%, n=1,143) or capillary blood (18%, n=249). CXR  
45 images were collected digitally for 1,148 (83%), and analog images were scanned for 244  
46 (18%). The distribution of each novel test quantitative result by microbiologic reference  
47 standard category is presented in the Appendix (**Appendix Table S2**). There were no adverse  
48 events from any testing.

49

1 The AUC for CAD4TB was 0.90 (95% CI 0.87, 0.92). Xpert HR had a similar AUC: 0.89 (95%  
2 CI 0.86, 0.91), and CRP only reached 0.81 (95% CI 0.79, 0.84) (**Figure 2**). ROC analysis  
3 against the sputum Xpert reference standard is available in the Appendix (**Figure S2**).  
4

5 Against the microbiologic reference standard and at a sensitivity of 90%, CAD4TB (TB score  
6  $\geq 28.61$ ) achieved the highest specificity 70.3% (95% CI 67.5, 73.0), and Xpert HR (TB score  
7  $\leq -1.3$ ) achieved a specificity of 65.1% (95% CI 62.2, 67.9). CRP with a cut-off of  $\geq 2.81$  mg/L  
8 achieved a specificity of 49.7% (95% CI 46.7, 52.7). At the WHO-recommended cut-point of  
9  $\geq 5$  mg/L, sensitivity of CRP was 82.8% (95% CI 78.1, 86.9) and specificity 64.8% (95% CI  
10 61.9, 67.7).  
11

12 Evaluating CAD4TB, Xpert HR, and CRP in comparison using these cut-points, CAD4TB  
13 performs best, with a specificity of 5.2% (95% CI 1.6, 8.9) greater than Xpert HR, and 20.6%  
14 (95% CI 17.0, 24.3) greater than CRP (**Table 2**). Accuracy against the sputum Xpert Ultra  
15 alone is presented in the Appendix (**Table S6**).  
16


17 **Two-test screening algorithms.** We found that 417 pairs of cut points for a combined Xpert  
18 HR- CAD4TB test achieved TPP targets when using a sequential negative serial screening  
19 approach, and 31 pairs of cut points achieved TPP targets using a sequential positive serial  
20 screening approach (**Figure 3**). The selection process for other two-test screening algorithms  
21 is presented in the Appendix (**Figure S3-S4**). The optimal combination of CAD4TB and Xpert  
22 HR (cut-point for CAD4TB  $\geq 49.68$  and Xpert HR  $\leq -2.07$ ) achieved a specificity of 79.6%  
23 (95% CI 77.1, 82.0) with a sensitivity of 90%. This represents a 9.3% (95% CI 6.6, 11.9)  
24 improvement over CAD4TB alone, 14.5% improvement over Xpert HR alone (95% CI 11.4,  
25 17.6), and 29.9% over CRP alone (95% CI 26.5, 33.4; **Table 2**). Other two-step screening  
26 algorithms had lower accuracy. Using sequential negative serial screening, both Xpert HR-  
27 CAD4TB and CRP- CAD4TB met current TPP targets. Using sequential positive serial  
28 screening, only Xpert HR- CAD4TB met the current TPP targets (**Table 2**). The agreement  
29 between tests and test algorithms is reported in the Appendix (**Table S7**).  
30

31 **Subgroup analyses.** Using the same cut-points for the best-performing two-test screening  
32 algorithm (Xpert HR-CAD4TB using sequential negative serial screening), accuracy varied  
33 most notably by country, with sensitivity ranging from 62.1% (95% CI 42.3, 79.3) in the  
34 Philippines to 100% (95% CI 85.2, 100) in India. Sensitivity was similar among people with  
35 and without HIV (89.5% vs. 90.2%) and people with and without diabetes (sensitivity 91.7%  
36 vs. 89.7%); specificity was similar among people with and without diabetes (77.2% vs. 80.0%)  
37 and slightly higher among people without HIV (81.1% vs. 71.1% among PLHIV; **Appendix**  
38 **Figure S5**). Females had lower sensitivity (81.4% vs. 94.2% among males), but higher  
39 specificity (85.4% vs. 74.0%, **Appendix Figure S5**). Subgroup analyses of other combined  
40 tests are presented in the Appendix (**Figures S6-S8**).  
41

42 Using subgroup-specific cut-points, all one- and two-step screening algorithms except CRP  
43 alone were able to achieve 90% sensitivity among participants in the Philippines (n/N=29/326  
44 with MRS-positive TB) and among females (n/N=95/623 with MRS-positive TB). No  
45 screening algorithms met TPP targets among females, and only one screening algorithm,  
46 defined by Xpert HR  $\leq -0.658$  and CAD4TB  $\geq 6.727$  met TPP targets among participants in the  
47 Philippines, with a specificity  $>70\%$  (**Appendix Table S3**).  
48

49 In a hypothetical cohort of 1,000 people with presumed TB, assuming a TB prevalence of 10%,  
50 the best-performing combined test would achieve a positive predictive value of 32.8% (95%

1 CI 27.3, 38.8) and a negative predictive value of 98.6% (95% CI 97.5, 99.3) (**Appendix Table**  
 2 **S4**). Performing CAD4TB-Xpert HR using sequential negative serial screening (positive  
 3 defined as CAD4TB  $\geq$ 49.68 or Xpert HR  $\leq$ -2.07), followed by sputum testing if positive, would  
 4 avert 726 sputum tests vs. 643 sputum tests averted if using CAD4TB alone (**Appendix Table**  
 5 **S5**). Both screening strategies would miss 10 (10%) people with TB. However, to achieve this  
 6 accuracy, performing CAD4TB-Xpert HR using sequential negative serial screening would  
 7 require 73-77% of participants to receive a second screening test depending on order  
 8 (**Appendix Table S5**).  
 9



10 **Figure 1. Study population.** Note. Culture is not performed for participants with positive  
 11 results on sputum Xpert Ultra.  
 12


**Table 1. Demographic and clinical characteristics by country**

	Total (N=1,392)	Philippines (N=326)	Vietnam (N=276)	Uganda (N=267)	South Africa (N=262)	India (N=261)
Age, mean ± SD (years)	43 ± 16	40 ± 15	51 ± 16	34 ± 12	40 ± 12	48 ± 16
Female	633 (45%)	181 (56%)	108 (39%)	112 (42%)	125 (48%)	107 (41%)
Body mass index (BMI), mean ± SD	23 ± 5	24 ± 5	20 ± 3	22 ± 4	24 ± 7	23 ± 6
Person living with HIV	197 (14%)	3 (1%)	2 (1%)	80 (30%)	102 (40%)	10 (4%)
CD4 count, median (IQR)	378 (210-651)	527 (184-812)	547 (497-597)	360 (222-634)	335 (204-660)	587 (220-692)
Person living with diabetes	196 (14%)	42 (13%)	65 (24%)	25 (9%)	17 (6%)	47 (18%)
Prior TB diagnosis	271 (19%)	43 (13%)	58 (21%)	32 (12%)	100 (38%)	38 (15%)
<b>Symptoms</b>						
Cough ≥2 weeks	1392 (100%)	326 (100%)	276 (100%)	267 (100%)	262 (100%)	261 (100%)
Fever	489 (35%)	50 (15%)	98 (36%)	184 (69%)	93 (35%)	64 (25%)
Hemoptysis	170 (12%)	23 (7%)	61 (22%)	44 (16%)	19 (7%)	23 (9%)
Night sweats	474 (34%)	56 (17%)	89 (32%)	167 (63%)	136 (52%)	26 (10%)
Weight loss	639 (46%)	91 (28%)	79 (29%)	187 (70%)	168 (64%)	114 (44%)
Loss of appetite	515 (37%)	75 (23%)	73 (26%)	157 (59%)	114 (44%)	96 (37%)
<b>Reference standards</b>						
Sputum Xpert Ultra Reference Standard						
TB Negative	1114 (80%)	304 (93%)	183 (66%)	176 (66%)	213 (81%)	238 (91%)
TB Positive	274 (20%)	22 (7%)	93 (34%)	90 (34%)	47 (18%)	22 (8%)
Indeterminate	4 (0%)	0 (0%)	0 (0%)	1 (0%)	2 (1%)	1 (0%)
Highest semiquantitative grade						
Trace	6 (2%)	1 (5%)	0 (0%)	3 (3%)	2 (4%)	0 (0%)
Very low	43 (16%)	5 (23%)	14 (15%)	10 (11%)	10 (20%)	4 (18%)
Low	85 (31%)	8 (36%)	37 (40%)	19 (21%)	12 (24%)	9 (41%)
Medium	68 (25%)	6 (27%)	21 (23%)	23 (25%)	12 (24%)	6 (27%)
High	75 (27%)	2 (9%)	21 (23%)	36 (40%)	13 (27%)	3 (14%)
Microbiologic reference standard						
TB Negative	1089 (78%)	297 (91%)	171 (62%)	174 (65%)	209 (80%)	238 (91%)



TB Positive	303 (22%)	29 (9%)	105 (38%)	93 (35%)	53 (20%)	23 (9%)
<b>Sample collection</b>						
Blood collection method						
Venous	1143 (82%)	326 (100%)	276 (100%)	267 (100%)	13 (5%)	261 (100%)
Capillary	249 (18%)	0 (0%)	0 (0%)	0 (0%)	249 (95%)	0 (0%)
CXR type						
Digital	1148 (82%)	326 (100%)	276 (100%)	23 (9%)	262 (100%)	261 (100%)
Analog	244 (18%)	0 (0%)	0 (0%)	244 (91%)	0 (0%)	0 (0%)

Missing HIV-status for 6 participants in South Africa.



**Figure 2. Receiver operating characteristic curve.** ROC curves against the microbiologic reference standard with AUC and 95% CI displayed for CAD4TB, Xpert HR, and CRP. The upper-left area shaded in gray notes the region where tests meet TPP targets ( $\geq 90\%$  sensitivity,  $\geq 70\%$  specificity). N=1,392 participants from the Philippines, Vietnam, Uganda, South Africa, and India with presumptive TB (n=303, 22% with microbiologically confirmed TB).


**Table 2. Head-to-head comparison of diagnostic accuracy at primary cut-points.** Cut-points were chosen to achieve  $\geq 90\%$  sensitivity and maximize specificity against the microbiologic reference standard in the overall study population.

	Quantitative value indicating positive test	Specificity (95% CI)	Absolute difference in specificity (95% CI)		
			vs. CAD4TB	vs. Xpert HR	vs. CRP
<b>One-step screening</b>					
<b>CAD4TB*</b>	TB score $\geq 28.61$	70.3% (67.5, 73.0%)	-	5.2% (1.6, 8.9)	20.6% (17.0, 24.3)
<b>Xpert HR</b>	TB score $\leq -1.3$	65.1% (62.2, 67.9)	-5.2% (-8.9, -1.6)	-	15.4% (11.9, 19.0)
<b>CRP</b>	$\geq 2.81$ mg/L	49.7% (46.7, 52.7)	-20.6% (-24.3, -17.0)	-15.4% (-19.0, -11.9)	-
<b>Two-step screening using sequential negative serial screening</b>					
<b>Xpert HR- CAD4TB*</b>	CAD $\geq 49.68$ or Xpert HR $\leq -2.07$	79.6% (77.1, 82.0)	9.3% (6.6, 11.9)	14.5% (11.4, 17.6)	29.9% (26.5, 33.4)
<b>CRP- CAD4TB *</b>	CRP $\geq 51.38$ mg/L or CAD $\geq 37.77$	75.9% (73.3, 78.5)	5.6% (3.7, 7.5)	10.8% (7.4, 14.3)	26.3% (22.8, 29.7)
<b>CRP-Xpert HR</b>	CRP $\geq 66.66$ or Xpert HR $\leq -1.34$	64.2% (61.3, 67.0)	-6.2% (-9.7, -2.6)	-0.9% (-2.0, -0.2)	14.5% (11.1, 17.9)
<b>Two-step screening using sequential positive serial screening</b>					
<b>Xpert HR-CAD4TB*</b>	Xpert HR $\leq -0.81$ and CAD $\geq 24.87$	73.7% (71.0, 76.3)	3.4% (1.5, 5.3)	8.6% (5.4, 11.9)	24.1% (20.6, 27.5)
<b>CRP-CAD4TB</b>	CRP has no added value	-	-	-	-
<b>CRP-Xpert HR</b>	CRP has no added value	-	-	-	-

CI: confidence interval; CAD: computer aided detection, represented by CAD4TB; CRP: C-reactive protein; HR: host response; TPP: target product profile

Note. The order of tests in two-step screening does not impact the accuracy.

\* Meets current TPP target ( $\geq 90\%$  sensitivity,  $\geq 70\%$  specificity)



**Figure 3. Selection of cut points for two-step screening algorithm combining Xpert HR and CAD4TB.** Panel (A) shows the possible cut-points using sequential negative serial screening, in which the second screening test is conducted only if the first is negative and a positive screen is defined as positive on either test. Panel (B) shows the possible cut-points using sequential positive serial screening, in which the second screening test is conducted only if the first is positive and a positive screen is defined as positive on both tests. The x-axis shows all potential cut-points for Xpert HR (test positive defined as less than or equal to the cut point chosen), and the y-axis shows all potential cut points for CAD4TB (test positive defined as greater than or equal to the cut point chosen). Each point on the graph corresponds to a pair of cut points used to define a positive screening algorithm. The colors represent the range of sensitivities and specificities possible. The outlined region contains pairs with sensitivity  $\geq 90\%$  and specificity  $\geq 70\%$  ( $n=417$  in panel A,  $n=31$  in panel B).

## DISCUSSION

Comparing CAD4TB, Xpert HR, and CRP, we found that CAD4TB was the most accurate TB triage test for pulmonary TB and the only test that met WHO TPP specificity targets ( $\geq 70\%$  at  $\geq 90\%$  sensitivity) in a multi-country cohort of people with presumptive TB. Combining CAD4TB with Xpert HR or CRP using a sequential negative serial screening algorithm further improved accuracy, while only a combination with Xpert HR improved performance when using sequential positive serial screening. There was some variability in performance by subgroup; therefore, subgroup-specific cut-points may be warranted for best performance with implementation.

The diagnostic accuracy of CAD4TB in combination with other screening tests has not been well-studied, given the cost and infrastructure needs for CAD4TB alone are substantial. Nevertheless, per-screen costs of certain CAD solutions, when used at scale, have proven to be less costly compared with a radiologist [20] and more effective in terms of timeliness and completeness of results when implemented in a PLHIV population [21].

In a hypothetical cohort of 1,000 people with 10% TB prevalence, adding Xpert HR to CAD4TB using sequential negative serial screening averted 83 additional Xpert Ultra tests compared to using CAD4TB alone (274 vs. 357 requiring sputum Xpert testing); however, about three-quarters would require two screening tests prior to sputum testing (235 X-rays and CAD averted compared to CAD4TB alone). A sequential positive serial screening algorithm using the same tests would avert 288 X-rays compared to CAD4TB alone but require more confirmatory sputum testing (327 requiring sputum Xpert testing). Cost, however, is likely to be a major limitation of the implementation of a CAD4TB-Xpert HR screening approach, given that recent data showed the Xpert HR cartridge is unlikely to achieve cost-effectiveness if implemented alone [22]. While CRP-CAD would result in slightly decreased specificity using a sequential negative serial screening (3.7% less than Xpert HR-CAD4TB), it would avert 149 CAD4TB/CXR and 693 Xpert Ultra and thus warrants consideration from an economic standpoint. An analysis for Uganda of a CRP-CAD4TB algorithm suggested it could be cost-effective [23].

Beyond cost, uptake of this intervention may be limited by access to the equipment needed (X-ray systems, GeneXpert instrument), especially at lower-level health facilities. Furthermore, the time it takes to complete screening using both screening tests may also reduce the effectiveness of this algorithm. A more cost-efficient two-stage screening algorithm would wait until the first test result (e.g., CRP or Xpert HR) comes back before running the second test (e.g., CAD4TB). This two-step approach is considered currently by the WHO in the revision of the TPP for TB screening. However, the added steps may further delay diagnosis or result in loss to follow-up, and this needs to be further studied with implementation [23].

We found that performance varied by country and sex could be mitigated by using subgroup-specific cut-points for test positivity. Tailoring guidelines for use will be important, as using universal cut-points may miss key subgroups. However, at the same time, different cut-offs might increase the complexity of validation for policy purposes and implementation.

Strengths of this study include its population: a large, well-characterized, diverse cohort of adults with presumptive TB across five countries. Prospective and concurrent evaluation of multiple TB triage tests allowed for a head-to-head comparison of these tests. This study is methodologically robust, with consistent implementation across sites and a thorough microbiological reference standard. However, several limitations should be considered in the

interpretation of these findings: (1) The prevalence of TB differed across study sites, ranging from 9-38%, which may also suggest differing states of TB disease at the time of presentation across sites, which may explain at least some heterogeneity across sites; (2) limited generalizability beyond pulmonary TB; these results apply only to symptomatic pulmonary TB, and performance may differ in people unable to provide sputum and those with extrapulmonary TB.

In conclusion, current versions of CAD4TB achieve TPP targets for a TB triage test and outperform Xpert HR and CRP. Combining screening tests in algorithms further increases accuracy, but cost and implementation feasibility of these screening approaches will need to be evaluated.

**Author contributions:** PN, AC, and CMD conceptualized the study. RC, PPJP, AC, AGW, and CMD designed the model framework. BT, VD, WD, AA, DVN, WW, CY, NVN, GT, and DJC collected the data. RC curated the data. RC, PPJP, and AGW conducted formal analysis. RC and PPJP visualized the data. RC, BT, WD, AA, AGW, and CMD drafted the manuscript. All authors edited and approved the manuscript.

## References

1. World Health Organization. Global Tuberculosis Report. Geneva, Switzerland, **2023** 7 November 2023.
2. WHO. High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland. Geneva: World Health Organization, **2014** 2014.
3. Nathavitharana RR, Yoon C, MacPherson P, et al. Guidance for studies evaluating the accuracy of tuberculosis triage tests. *The Journal of infectious diseases* **2019**; 220(Supplement\_3): S116-S25.
4. Kik SV, Gelaw SM, Ruhwald M, et al. Diagnostic accuracy of chest X-ray interpretation for tuberculosis by three artificial intelligence-based software in a screening use-case: an individual patient meta-analysis of global data. *medRxiv* **2022**: 2022.01.24.22269730.
5. Gelaw SM, Kik SV, Ruhwald M, et al. Diagnostic accuracy of three computer-aided detection systems for detecting pulmonary tuberculosis on chest radiography when used for screening: Analysis of an international, multicenter migrants screening study. *PLOS Glob Public Health* **2023**; 3(7): e0000402.
6. Qin ZZ, Barrett R, Del Mar Castro M, et al. Early user experience and lessons learned using ultra-portable digital X-ray with computer-aided detection (DXR-CAD) products: A qualitative study from the perspective of healthcare providers. *PLoS One* **2023**; 18(2): e0277843.
7. Biewer AM, Tzelios C, Tintaya K, et al. Accuracy of digital chest x-ray analysis with artificial intelligence software as a triage and screening tool in hospitalized patients being evaluated for tuberculosis in Lima, Peru. *PLOS Glob Public Health* **2024**; 4(2): e0002031.
8. Qin ZZ, Barrett R, Ahmed S, et al. Comparing different versions of computer-aided detection products when reading chest X-rays for tuberculosis. *PLOS Digit Health* **2022**; 1(6): e0000067.
9. Kagujje M, Kerkhoff AD, Nteeni M, Dunn I, Mateyo K, Muyoyeta M. The Performance of Computer-Aided Detection Digital Chest X-ray Reading Technologies for Triage of Active Tuberculosis Among Persons With a History of Previous Tuberculosis. *Clin Infect Dis* **2023**; 76(3): e894-e901.
10. Tavaziva G, Majidulla A, Nazish A, et al. Diagnostic accuracy of a commercially available, deep learning-based chest X-ray interpretation software for detecting culture-confirmed pulmonary tuberculosis. *Int J Infect Dis* **2022**; 122: 15-20.
11. Reeve BW, Ndlangalavu G, Mishra H, et al. Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective diagnostic accuracy study. *medRxiv* **2023**.
12. Calderwood CJ, Reeve BW, Mann T, et al. Clinical utility of C-reactive protein-based triage for presumptive pulmonary tuberculosis in South African adults. *Journal of Infection* **2023**; 86(1): 24-32.
13. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. *The International journal of tuberculosis and lung disease* **2013**; 17(5): 636-43.

14. Derendinger B, Mochizuki TK, Marcelo D, et al. C-reactive protein-based tuberculosis triage testing: a multi-country diagnostic accuracy study. medRxiv **2024**: 2024.04.23.24305228.
15. Sutherland JS, van der Spuy G, Gindeh A, et al. Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results. *Clinical Infectious Diseases* **2022**; 74(12): 2136-41.
16. Gupta-Wright A, Ha H, Abdulgadar S, et al. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. *Lancet Glob Health* **2024**; 12(2): e226-e34.
17. Worodria W, Castro R, Kik SV, et al. An independent, multi-country head-to-head accuracy comparison of automated chest x-ray algorithms for the triage of pulmonary tuberculosis. medRxiv **2024**: 2024.06.19.24309061.
18. Organization WH. Module 2: Screening WHO Operational Handbook on Tuberculosis Systematic Screening for Tuberculosis Disease. **2021**.
19. Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. *BMJ Open* **2016**; 6(11): e012799.
20. Bashir S, Kik SV, Ruhwald M, et al. Economic analysis of different throughput scenarios and implementation strategies of computer-aided detection software as a screening and triage test for pulmonary TB. *PLoS One* **2022**; 17(12): e0277393.
21. MacPherson P, Webb EL, Kamchedzera W, et al. Computer-aided X-ray screening for tuberculosis and HIV testing among adults with cough in Malawi (the PROSPECT study): A randomised trial and cost-effectiveness analysis. *PLoS Med* **2021**; 18(9): e1003752.
22. Brümmer LE, Thompson RR, Malhotra A, et al. Cost effectiveness of low-complexity screening tests in community-based case-finding for tuberculosis. *Clin Infect Dis* **2023**.
23. Murray M, Cattamanchi A, Denkinge C, Van't Hoog A, Pai M, Dowdy D. Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. *BMJ Glob Health* **2016**; 1(2): e000064.